Plant Name: Imperata cylindrica
Taxonomic Information:
Plant ID: NPO23628
Plant Latin Name: Imperata cylindrica
Taxonomy Genus: Imperata
Taxonomy Family: Poaceae
Plant External Links:
NCBI TaxonomyDB:
80369
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Australia; Guinea; Tanzania; Indonesia; India; Laos; Malaysia; Rwanda; China; Vietnam; Thailand; Kenya; South Korea; PhilippinesTraditional Medicine System:
Indian Folk; TCM; Ayurveda; SiddhaMedicinal Functions:
Anthelmintic; Antibacterial; Antivinous; Astringent; Cancer; Diuretic; Emollient; Febrifuge; Restorative; Sialagogue; Styptic; Tonic
Geographical Distribution:
Australia; Guinea; Philippines; Indonesia; India; Malaysia; Rwanda; China; Vietnam; Laos; Kenya; South Korea; Tanzania; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; FFAR4; DRD1; DRD3; DRD2; | |
| NPSR1; | |
| TDP1; ALOX15; | |
| CA2; CA14; CA9; | |
| NR1H4; | |
| FABP3; LMNA; F3; SIGMAR1; FABP4; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 6.180E-08 | 6.728E-04 | DRD1, DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 3.145E-07 | 6.849E-04 | DRD1, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 3.145E-07 | 6.849E-04 | DRD1, DRD2, DRD3 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.997E-07 | 8.370E-04 | CA14, CA2, CA9 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 1.248E-06 | 1.430E-03 | DRD1, DRD2, DRD3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.440E-06 | 2.415E-03 | CA2, DRD1, DRD2, DRD3, NPSR1 |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 2.833E-06 | 2.682E-03 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 3.375E-06 | 2.875E-03 | DRD2, DRD3 |
| BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 3.565E-06 | 2.875E-03 | DRD1, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 3.185E-06 | 2.875E-03 | FABP3, FABP4, FFAR4 |
| BP | GO:0009987; cellular process | GO:0050709; negative regulation of protein secretion | 8.074E-06 | 5.137E-03 | DRD2, DRD3, FFAR4, NR1H4 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.124E-05 | 5.770E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 1.124E-05 | 5.770E-03 | DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.425E-05 | 6.603E-03 | CA14, CA2, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.684E-05 | 6.919E-03 | CYP1A2, CYP2C19 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.672E-05 | 6.919E-03 | DRD1, DRD2, DRD3, F3, FFAR1, FFAR4, NPSR1, NR1H4, SIGMAR1 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.856E-05 | 7.485E-03 | DRD1, DRD2, DRD3 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 1.949E-05 | 7.718E-03 | ALOX15, CA2, CYP1A2, DRD2, FABP4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.720E-07 | 2.554E-05 | CA2, CA9, CA14 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.582E-06 | 6.806E-05 | CYP1A2, ALOX15, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 3.202E-04 | 4.056E-03 | DRD1, DRD2, DRD3 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; DRD3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; FFAR1; |
| NA: NA | Itching | NA | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; CA9; |
| NA: NA | Vomiting | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; DRD3; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; DRD3; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| NA: NA | Edema | NA | CA2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| NA: NA | Hyperaemia | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | DRD2; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
